Baird Maintains Neutral on Quest Diagnostics, Raises Price Target to $236

Benzinga Newsdesk www.benzinga.com Neutral 49.0%

Neg 0% Neu 49% Pos 0%

Baird analyst Eric Coldwell maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $232 to $236.